Department of Emergency Medicine, The Ohio State University, OH 43210, USA.
Department of Internal Medicine, The Ohio State University, OH 43210, USA.
Pain Manag. 2021 Sep;11(5):437-449. doi: 10.2217/pmt-2021-0002. Epub 2021 Apr 12.
Migraine is a leading cause of morbidity and disability worldwide. Triptans were the first migraine-specific drug class developed and have proven efficacy in treatment of this neurological disease. They are however contraindicated in patients with cardiovascular disease and possibly others, owning to their vasoconstrictive properties. This review will focus on lasmiditan, which has been called the first 'ditan' and 'neurally acting anti-migraine agent', designed to selectively agonize the serotonin 5-HT receptor subtype, providing anti-migraine effects without concomitant vasoconstriction. To date, lasmiditan has proven safe and effective for the acute treatment of migraine in two Phase II and four Phase III trials. analysis revealed that the majority of treatment-emergent adverse events were CNS-related, mild-to-moderate in severity and self-limiting. The US FDA label recommends that patients not drive or operate machinery until at least 8 h after taking each dose of lasmiditan.
偏头痛是全球范围内导致发病和残疾的主要原因。曲坦类药物是开发的首个偏头痛特异性药物类别，已被证明对治疗这种神经系统疾病有效。然而，由于其血管收缩特性，它们在心血管疾病患者及其他患者中被禁用。本综述将重点介绍拉米地坦，它被称为首个“二坦”和“作用于神经的抗偏头痛药物”，旨在选择性激动 5-羟色胺 5-HT 受体亚型，提供抗偏头痛作用而无伴随的血管收缩。迄今为止，拉米地坦在两项 II 期和四项 III 期试验中已被证明可安全有效地用于偏头痛的急性治疗。分析显示，大多数治疗中出现的不良事件与中枢神经系统相关，严重程度为轻度至中度，且具有自限性。美国 FDA 标签建议患者在服用拉米地坦后至少 8 小时内不要驾驶或操作机器。
